NSCLC

[Iovance Biotherapeutics, Inc.] Iovance Biotherapeutics, Inc. announced that the US FDA has allowed an IND to proceed for its first genetically modified TIL therapy, IOV-4001, for the treatment of unresectable or metastatic melanoma and stage III or IV NSCLC.

[Cell Reports Medicine] Investigators demonstrated that AXL was a critical targetable driver of immune suppression in STK11/LKB1 mutant NSCLC.

[Cancer Immunology Immunotherapy] Large cohorts of non-small cell lung cancer patients from The Cancer Genome Atlas and a single-cell sequencing dataset were integrated to illustrate immunosuppressive phenotypes of tumor-associated macrophages, followed by experimental verification.

[Immunity] Although PD-1 and TIGIT are thought to regulate different costimulatory receptors, effectiveness of PD-1 or TIGIT inhibition in preclinical tumor models was reduced in the absence of CD226.

[British Journal of Cancer] The authors summarize the main clinical applications of liquid biopsy in advanced NSLC, underlining both its potential and limitations from a clinically driven perspective.

[Clinical Cancer Research] In a Phase I/Ib, dose-escalation/expansion study, patients with advanced/metastatic non-small cell lung cancer and 1 prior therapy received taminadenant with or without spartalizumab.